Arrowhead Pharmaceuticals Inc. (ARWR)

19.46
NASDAQ : Health Technology
Prev Close 19.47
Day Low/High 19.20 / 19.95
52 Wk Low/High 9.44 / 22.39
Avg Volume 1.40M
Exchange NASDAQ
Shares Outstanding 94.81M
Market Cap 1.85B
EPS -0.70
P/E Ratio 278.14
Div & Yield N.A. (N.A)
'Fast Money' Recap: Next Stop, S&P 2,100?

'Fast Money' Recap: Next Stop, S&P 2,100?

The trading panel looked at banks and the top buy and sell candidates for right now.

First Week of ARWR October 18th Options Trading

First Week of ARWR October 18th Options Trading

Investors in Arrowhead Research Corp saw new options become available this week, for the October 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new October 18th contracts and identified one put and one call contract of particular interest.

5 Stocks Jumping on Unusual Volume

5 Stocks Jumping on Unusual Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Stock To Watch: Arrowhead Research (ARWR) In Perilous Reversal

Stock To Watch: Arrowhead Research (ARWR) In Perilous Reversal

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

ARWR November 22nd Options Begin Trading

ARWR November 22nd Options Begin Trading

Investors in Arrowhead Research Corp saw new options become available today, for the November 22nd expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 99 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

'Mad Money' Lightning Round: Don't Buy IBM Right Now

'Mad Money' Lightning Round: Don't Buy IBM Right Now

Cramer says he's avoiding Potbelly but likes Opko Health and Hawaiian Holdings.

Jim Cramer's 'Mad Money' Recap: Now That's More Like It

Jim Cramer's 'Mad Money' Recap: Now That's More Like It

When the consensus changes, the buyers change, too, and that's why Tuesday's stocks were being bought Wednesday, Cramer says.

Arrowhead Discloses First Human Hepatitis B Therapy Results

Arrowhead Discloses First Human Hepatitis B Therapy Results

The announcement is short on specific details but the Arrowhead drug, ARC-520, appears to have passed through its first clinical hurdle in hepatitis B patients relatively well.

Arrowhead Reports Fiscal 2014 Third Quarter Financial Results And Provides Update On ARC-520

Arrowhead Reports Fiscal 2014 Third Quarter Financial Results And Provides Update On ARC-520

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2014 third quarter ended June 30, 2014 and provided an...

Bullish Two Hundred Day Moving Average Cross - ARWR

Bullish Two Hundred Day Moving Average Cross - ARWR

In trading on Monday, shares of Arrowhead Research Corp crossed above their 200 day moving average of $13.14, changing hands as high as $13.50 per share. Arrowhead Research Corp shares are currently trading up about 2% on the day.

Today's Dead Cat Bounce Stock Is Arrowhead Research (ARWR)

Today's Dead Cat Bounce Stock Is Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Biotech Stock Mailbag: Arrowhead, Catalyst Pharma

Biotech Stock Mailbag: Arrowhead, Catalyst Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Arrowhead To Report Fiscal 2014 Third Quarter Financial Results

Arrowhead To Report Fiscal 2014 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 third quarter ended June...

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

'Fast Money' Recap: Playing China Through U.S. Stocks

'Fast Money' Recap: Playing China Through U.S. Stocks

The trading panel looked at the Shanghai composite index and how investors can use U.S. stocks as a proxy.

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Interesting ARWR Put And Call Options For March 2015

Interesting ARWR Put And Call Options For March 2015

Investors in Arrowhead Research Corp saw new options begin trading this week, for the March 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

ARWR Makes Bullish Cross Above Critical Moving Average

ARWR Makes Bullish Cross Above Critical Moving Average

In trading on Monday, shares of Arrowhead Research Corp crossed above their 200 day moving average of $12.66, changing hands as high as $12.84 per share. Arrowhead Research Corp shares are currently trading up about 3.2% on the day.

14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014

14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014

Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

'Fast Money' Recap: Waiting for the Dust to Settle

'Fast Money' Recap: Waiting for the Dust to Settle

The trading panel discussed the market's fall and how to hedge your positions.

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Interesting ARWR Put And Call Options For August 16th

Interesting ARWR Put And Call Options For August 16th

Investors in Arrowhead Research Corp saw new options become available this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Arrowhead Research (ARWR) Showing Signs Of Perilous Reversal Today

Arrowhead Research (ARWR) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Arrowhead Announces New Clinical Candidate ARC-AAT For Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Arrowhead Announces New Clinical Candidate ARC-AAT For Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced its next clinical candidate ARC-AAT, an RNAi therapeutic designed to treat liver disease...

Today's Dead Cat Bounce Stock: Arrowhead Research (ARWR)

Today's Dead Cat Bounce Stock: Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Arrowhead Research Set To Join Russell 3000 Index

Arrowhead Research Set To Join Russell 3000 Index

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its...

Arrowhead Issues A Statement On Intellectual Property Protection For ARC-520

Arrowhead Issues A Statement On Intellectual Property Protection For ARC-520

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today reaffirmed its belief that it has broad access to intellectual property required to develop...

Arrowhead To Host Analyst Day To Discuss New Rare Liver Disease Candidate

Arrowhead To Host Analyst Day To Discuss New Rare Liver Disease Candidate

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host an analyst day on June 19, 2014 at 12:30 p.

TheStreet Quant Rating: D (Sell)